Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening

- Histologically or cytologically documented advanced or metastatic solid tumors for
which established therapy either does not exist or has proven ineffective or
intolerable

- Life expectancy greater than or equal to (>=) 12 weeks

- Adequate hematologic and end organ function

- For female participants of childbearing potential and male participants with partners
of childbearing potential, agreement (by participant and/or partner) to use highly
effective forms of contraception and to continue its use for the duration of the study
and for 4 months after last dose of study treatment (for females) and 6 months after
last dose of study treatment (for males)

Exclusion Criteria:

- Prior anti-cancer therapy that fulfills the following criteria: a total of more than
three (Arms A and B) or two (Arms C and D) prior cytotoxic chemotherapy regimens,
high-dose chemotherapy requiring stem-cell support, and irradiation to >=25 percent
(%) of bone marrow-bearing areas

- Treatment with chemotherapy, hormonal therapy (except hormone replacement therapy,
oral contraceptives, or gonadotropin-releasing hormone (GnRH) agonists or antagonists
for prostate cancer), immunotherapy, biologic therapy, radiation therapy (except
palliative radiation to bony metastases), or herbal therapy as cancer therapy within 4
weeks prior to initiation of ipatasertib. Exceptions are kinase inhibitors approved by
local regulatory authorities, which may be used within 2 weeks prior to initiation of
ipatasertib, provided that any clinically-relevant drug-related toxicity has
completely resolved and prior approval is obtained from the Medical Monitor

- Palliative radiation to bony metastases within 2 weeks prior to initiation of
ipatasertib

- History of Type 1 or Type 2 diabetes requiring regular medication

- Grade >= 2 heart failure or history of unstable angina

- History of clinically significant ventricular arrhythmias or active ventricular
arrhythmia requiring medication

- For Arm D only: History of seizure, unexplained loss of consciousness, transient
ischemic attack within 12 months of enrollment, cerebral vascular accident, and any
brain metastases